294 related articles for article (PubMed ID: 30549002)
1. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
Park S; Greenberg P; Yucel A; Farmer C; O'Neill F; De Oliveira Brandao C; Fenaux P
Br J Haematol; 2019 Jan; 184(2):134-160. PubMed ID: 30549002
[TBL] [Abstract][Full Text] [Related]
2. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Chung EY; Palmer SC; Saglimbene VM; Craig JC; Tonelli M; Strippoli GF
Cochrane Database Syst Rev; 2023 Feb; 2(2):CD010590. PubMed ID: 36791280
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M
J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.
Aslaner Ak M; Gedük A; Acar İH; Polat MG; Sunu C; Bolaman AZ; Hacıbekiroğlu T; Güvenç B; Ertop Ş
Turk J Haematol; 2023 May; 40(2):92-100. PubMed ID: 36799095
[TBL] [Abstract][Full Text] [Related]
6. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
8. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
Gabrilove J; Paquette R; Lyons RM; Mushtaq C; Sekeres MA; Tomita D; Dreiling L
Br J Haematol; 2008 Jul; 142(3):379-93. PubMed ID: 18540943
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis.
Park S; Fenaux P; Greenberg P; Mehta B; Callaghan F; Kim C; Tomita D; Xu H
Br J Haematol; 2016 Sep; 174(5):730-47. PubMed ID: 27214305
[TBL] [Abstract][Full Text] [Related]
10. Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols.
Gascón P; Krendyukov A; Mathieson N; Aapro M
Leuk Res; 2019 Jun; 81():35-42. PubMed ID: 31005849
[TBL] [Abstract][Full Text] [Related]
11. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
[TBL] [Abstract][Full Text] [Related]
12. Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon?
Fattizzo B; Rizzo L; Giannotta JA; Mazzon F; Cecchi N; Frangi C; Barcellini W; Riva M
Br J Haematol; 2021 Nov; 195(4):e147-e150. PubMed ID: 34312838
[No Abstract] [Full Text] [Related]
13. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.
Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S
Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032
[TBL] [Abstract][Full Text] [Related]
14. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
Hörl WH
Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
[TBL] [Abstract][Full Text] [Related]
15. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
Kelaidi C; Fenaux P
Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
[TBL] [Abstract][Full Text] [Related]
17. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
[TBL] [Abstract][Full Text] [Related]
18. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.
Duong VH; Baer MR; Hendrick F; Weiss SR; Sato M; Zeidan AM; Gore SD; Davidoff AJ
Leuk Res; 2015 Jun; 39(6):586-91. PubMed ID: 25869077
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study.
Kim Y; Park SK; Cho WY; Joo KW; Shin SK; Kim DJ; Kim YL; Son SH; Chung W; Lee KY; Park SK; Kim JK; Kim SW; Kang DH; Kim JK; Jeon JS; Lee KW; Lee CH; Oh DJ; An WS; Lee JS; Kang GW; Do JY; Lee JP; Jin K
BioDrugs; 2020 Feb; 34(1):99-110. PubMed ID: 31749113
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT
Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
